Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a targeted oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, today announced the appointment of Dr Barry Davies as CSO, where he will lead the Company’s scientific strategy and Research and Development team. Barry joins Mosaic with over 25 years of experience in drug discovery, including 19 years at AstraZeneca where he most recently held the position of Senior Director, Global Project Leader. During his time with AstraZeneca, he led multiple projects across phases from lead optimization to phase 2 proof-of-concept clinical trials, mainly in the cell signaling, apoptosis, and DNA damage response areas and led preclinical work on multiple drug discovery programs, including the recently approved Capivasertib/Truqap.
Prior to this, Barry held other senior leadership roles at AstraZeneca, including Senior Director, Clinical and Translational Scientific Alliances, in which he was responsible for partnerships and collaborations in Europe and the Asia-Pacific region. Barry holds a BSc (Hons) Class I in Biochemistry and PhD in mechanisms of breast cancer metastasis from the University of Liverpool. Following postdoctoral work in the laboratory of Professor Bruce Ponder in Cambridge, he established his own research group at the Northern Institute for Cancer Research, University of Newcastle, where he was a group leader, senior lecturer, and Cancer .
